Susquehanna International Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-144,080
| Closed | -$1.44M | – | 13149 |
|
|
2025
Q2 | $1.44M | Buy |
144,080
+107,772
| +297% | +$868K | ﹤0.01% | 6557 |
|
|
2025
Q1 | $217K | Sell |
36,308
-197,568
| -84% | -$1.45M | ﹤0.01% | 10782 |
|
|
2024
Q4 | $1.8M | Buy |
233,876
+214,336
| +1,097% | +$1.84M | ﹤0.01% | 5560 |
|
|
2024
Q3 | $200K | Sell |
19,540
-89,535
| -82% | -$1.37M | ﹤0.01% | 10471 |
|
|
2024
Q2 | $1.62M | Buy |
109,075
+83,872
| +333% | +$1.2M | ﹤0.01% | 5501 |
|
|
2024
Q1 | $344K | Sell |
25,203
-260,115
| -91% | -$2.83M | ﹤0.01% | 9391 |
|
|
2023
Q4 | $3.12M | Buy |
285,318
+192,592
| +208% | +$1.91M | ﹤0.01% | 4493 |
|
|
2023
Q3 | $1.02M | Buy |
92,726
+18,345
| +25% | +$235K | ﹤0.01% | 6596 |
|
|
2023
Q2 | $985K | Buy |
74,381
+23,138
| +45% | +$330K | ﹤0.01% | 6714 |
|
|
2023
Q1 | $697K | Buy |
51,243
+10,996
| +27% | +$197K | ﹤0.01% | 7733 |
|
|
2022
Q4 | $786K | Sell |
40,247
-915
| -2% | -$17.9K | ﹤0.01% | 6712 |
|
|
2022
Q3 | $784K | Buy |
41,162
+23,347
| +131% | +$538K | ﹤0.01% | 7288 |
|
|
2022
Q2 | $367K | Sell |
17,815
-10,452
| -37% | -$248K | ﹤0.01% | 9010 |
|
|
2022
Q1 | $910K | Sell |
28,267
-48,583
| -63% | -$1.77M | ﹤0.01% | 7369 |
|
|
2021
Q4 | $3.58M | Buy |
+76,850
| New | +$2.56M | ﹤0.01% | 4344 |
|
|
2021
Q3 | – | Sell |
-26,939
| Closed | -$691K | – | 13143 |
|
|
2021
Q2 | $691K | Buy |
26,939
+6,747
| +33% | +$161K | ﹤0.01% | 8776 |
|
|
2021
Q1 | $690K | Buy |
+20,192
| New | +$730K | ﹤0.01% | 8700 |
|
Other funds holding ITOS
Susquehanna International Group's ITOS Position: Q3 2025 in Review
Susquehanna International Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 144,080 shares — an estimated $1.44M sold.
Susquehanna International Group first reported a position in ITOS in Q1 2021 and held it in 17 quarters. The position peaked at $3.58M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Susquehanna International Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 144,080 iTeos Therapeutics shares in Q3 2025, an estimated $1.44M.
- Susquehanna International Group first reported a position in iTeos Therapeutics in Q1 2021 and held it in 17 quarters.
- Susquehanna International Group's iTeos Therapeutics position peaked at $3.58M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.